



SUPPLEMENTARY FIG. S2. DMF protects against loss of striatal TH+ fibers. (A), immunohistochemistry with anti-TH antibody. (B), densitometric estimation of striatal dopaminergic terminals ($n=4-6$ animals per group). One-way ANOVA followed by Newman-Keuls post-test was used to assess significant differences among groups. Asterisks denote significant differences $*p < 0.05$, $**p < 0.01$, and $***p < 0.001$ comparing the indicated groups. (C) DA and DOPAC and DOPAC/DA levels in STR from Nrf2^{+/+} and Nrf2^{-/-} mice at 3 weeks ($n=3$ animals per group). Differences among groups were assessed by two-way ANOVA followed by Bonferroni's test. Asterisks denote significant differences with $*p < 0.05$, $**p < 0.01$ comparing the indicated groups. DA, dopamine; DOPAC, 3,4-dihydroxyphenylacetic acid.